35.92
0.72 (2.05%)
| Previous Close | 35.20 |
| Open | 34.00 |
| Volume | 16,427 |
| Avg. Volume (3M) | 107,257 |
| Market Cap | 1,576,571,776 |
| Price / Earnings (TTM) | 718.40 |
| Price / Sales | 136.20 |
| Price / Book | 64.85 |
| 52 Weeks Range | |
| Earnings Date | 28 Apr 2025 |
| Profit Margin | 28.99% |
| Operating Margin (TTM) | -68.64% |
| Diluted EPS (TTM) | 0.050 |
| Quarterly Revenue Growth (YOY) | -36.10% |
| Quarterly Earnings Growth (YOY) | 136.50% |
| Current Ratio (MRQ) | 10.71 |
| Operating Cash Flow (TTM) | 2.08 M |
| Levered Free Cash Flow (TTM) | 1.27 M |
| Return on Assets (TTM) | 7.18% |
| Return on Equity (TTM) | 14.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Anbio Biotechnology | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 4.78% |
| % Held by Institutions | 4.94% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Aug 2025 | Announcement | Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |